Comparative Cost-Effectiveness of Drugs in Early versus Late Stages of Cancer; Review of the Literature and a Case Study in Breast Cancer

Abstract

BackgroundMany oncological drugs that are being used in the adjuvant setting were first submitted for reimbursement in the metastatic stage, with differences in incremental cost-effectiveness ratios (ICERs) in both settings having potential implications for reimbursement and pricing. The aim of this study is to identify a possible trend in the cost-effectiveness for the early/adjuvant and late/metastatic stages of oncological drugs through review and case study.MethodsWe reviewed pairs of cost-effectiveness analyses of the same oncological drug in different stages for Scotland and the Netherlands. The case study in this report was directed at trastuzumab in the Dutch situation. Using a simplified Markov model, the cost-effectiveness in early and late stage of breast cancer was calculated and compared to the findings from the review.ResultsComparable studies were found for cetuximab, bortezomib and bosutinib. Treatments in the late stage were found to be more expensive per QALY by a factor ranging from 1.5 to 12. The case study provided a similar result; late stage treatment was more expensive by a factor 10. Using, for example, a threshold of €80,000/QALY, the early stage of cetuximab, bosutinib and trastuzumab are deemed cost-effective, while their compared late stage is lifted over the threshold and potentially considered not cost-effective.ConclusionICERs of oncological drugs used in different stages are more unfavourable in the late stage than in the early stage. Applying a reasonable threshold may result in early stage treatment being deemed cost-effective while late stage potentially not. Authorities should be aware of this when assessing oncological drugs and interpreting the corresponding ICERs, in the situation where oncological drugs are generally most submitted for reimbursement in the late stage initially.

Reviewing the quality, health benefit and value for money of chemotherapy and targeted therapy for metastatic breast cancer

“…This might indicate that value-based pricing might be on its way in this field, but that lower prices are needed in order to meet the willingness-to-pay threshold. On the other hand, assessing the value of money for treatments in the metastatic setting only is misleading because using these treatments in the adjuvant setting [ 55 ] or using them more efficiently (e.g. because experience has been acquired in clinical practice) might provide better value for money.…”

Low Overall Survival in Women With De Novo Metastatic Breast Cancer: Does This Reflect Tumor Biology or a Lack of Access to Health Care?

“…12,13 Individuals with metastatic conditions are generally given a continuous regimen of palliative treatment, which results in a high demand on health care facilities as a result of the constant need for tests, prescription of medication, and hospitalization for clinical support. 12,14,15 In low-and middle-income countries, there are additional problems, such as limited access to health care, with diagnosis often being made late and at more advanced stages, and the use of treatments below the already established standard. 16,17 For example, in the Brazilian public health care system, which provides care to approximately 70% of the country's population, trastuzumab became available for the treatment of metastatic HER2-positive breast cancer in 2017, almost 20 years after the US Food and Drug Administration approved the drug for use in the United States.…”

Modifiable risk factors for advanced vs. early breast cancer in the French E3N cohort

“…Early stage breast cancer remains strongly associated with better chances of survival and lighter treatments . In Western countries, breast cancers are diagnosed at an advanced stage (UICC Stage 2 and higher) in 30–40% of the cases, leading to heavier and more expensive treatments and to a higher risk of metastatic relapse than when diagnosed at Stage 1. Metastatic cancers are not curable, even if long survivals are now achievable …”